Hyphens Pharma International has granted the rights to commercialise its product Cerapro MED Skin Barrier Cream to Louis Widmer covering six European countries.
This is done via a licensing, supply and commercialisation agreement which spans Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.
The out-licensing agreement will result in Hyphens Pharma receiving an upfront fee and customary royalties on sales.
Cerapro is a patented formula which lowers skin pH and helps restore skin barrier. It targets atopic dermatitis, a common form of eczema.
CEO of Louis Widmer, Annemarie Widmer, says that Cerapro will be the new flagship product of the company's Remederm line, which is a leader in Europe in both specialist retailers and doctors for the care of dry, very dry and atopic skin.
Shares in Hyphens Pharma closed 1 cent higher or 2.985% up at 34.5 cents on Jan 5.
